- Home
- REI vs CTNM Comparison
REI vs CTNM Comparison
Compare REI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REI
- CTNM
- Stock Information
- Founded
- REI 2004
- CTNM 2009
- Country
- REI United States
- CTNM United States
- Employees
- REI N/A
- CTNM N/A
- Industry
- REI Oil & Gas Production
- CTNM
- Sector
- REI Energy
- CTNM
- Exchange
- REI Nasdaq
- CTNM Nasdaq
- Market Cap
- REI 171.0M
- CTNM 174.6M
- IPO Year
- REI N/A
- CTNM 2024
- Fundamental
- Price
- REI $0.93
- CTNM $7.38
- Analyst Decision
- REI
- CTNM Strong Buy
- Analyst Count
- REI 0
- CTNM 4
- Target Price
- REI N/A
- CTNM $22.50
- AVG Volume (30 Days)
- REI 3.4M
- CTNM 196.1K
- Earning Date
- REI 08-06-2025
- CTNM 08-05-2025
- Dividend Yield
- REI N/A
- CTNM N/A
- EPS Growth
- REI N/A
- CTNM N/A
- EPS
- REI 0.35
- CTNM N/A
- Revenue
- REI $318,900,835.00
- CTNM N/A
- Revenue This Year
- REI N/A
- CTNM N/A
- Revenue Next Year
- REI $9.98
- CTNM N/A
- P/E Ratio
- REI $2.70
- CTNM N/A
- Revenue Growth
- REI N/A
- CTNM N/A
- 52 Week Low
- REI $0.72
- CTNM $3.35
- 52 Week High
- REI $1.94
- CTNM $20.55
- Technical
- Relative Strength Index (RSI)
- REI 70.31
- CTNM N/A
- Support Level
- REI $0.79
- CTNM N/A
- Resistance Level
- REI $0.84
- CTNM N/A
- Average True Range (ATR)
- REI 0.05
- CTNM 0.00
- MACD
- REI 0.02
- CTNM 0.00
- Stochastic Oscillator
- REI 82.98
- CTNM 0.00
About REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.